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Objective: The objective of this study was to investigate whether a single 
nucleotide polymorphism (C to A transversion at position -163 downstream of 
the first transcribed nucleotide) in the enzyme that metabolizes caffeine 
(CYP1A2), would explain the variability seen in caffeine related responses in 
endurance exercise performance.  In a double blind crossover trial,  well 
trained male endurance athletes (n=11, mean VO2 max 69±4 mL.kg-1.min-1) 
ingested either caffeine (5 mg.kg-1) or a placebo 60 minutes prior to 
performing a lab based experimental protocol involving a two hour steady 
state cycle (70% VO2 max) followed by a 30 minute time trial to measure 
performance.  The rate of caffeine metabolism over seven hours (inclusive of 
exercise period) was also determined by the HPLC analysis of plasma 
caffeine and its major metabolites, paraxanthine, theophylline and 
theobromine.  Caffeine metabolism at rest over a similar seven hour period 
was also determined in the same manner.   
Results: Caffeine improved endurance performance by 7.1% (p=0.037) 
compared to a placebo.  Caffeine also significantly elevated heart rate during 
the time trial (p=0.003); and RPE (p=0.010) and VO2 (p=0.047) during steady 
state exercise.  There was no correlation between caffeine or paraxanthine 
concentrations at the start of the time trial and subsequent performance and 
the rate of caffeine metabolism was not significantly different between resting 
or exercising trials.  Furthermore there was no significant interaction between 
caffeine treatment and CYP1A2 genotype on performance or any other 
ii
variables measured.    However there was a trend for carriers of the C allele 
showing faster metabolism than those homozygous A/A (p=0.097).   
Conclusions:   Caffeine is ergogenic during endurance exercise, however 
individual responses were variable.  In this study this variability could not be 
explained by CYP1A2 genotype.  However the small sample size in this 
study especially when subjects were divided into genotype groups, makes 
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